about
Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysisClinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort studyEpidemiology of meningitis in an HIV-infected Ugandan cohortCost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settingsReconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcLIntegrating cryptococcal antigen screening and pre-emptive treatment into routine HIV careMultisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrastCryptococcus-Related Immune Reconstitution Inflammatory Syndrome (IRIS): Pathogenesis and its Clinical ImplicationsPaucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndromeMaltreatment of Strongyloides infection: case series and worldwide physicians-in-training surveyFighting the Monster: Applying the Host Damage Framework to Human Central Nervous System InfectionsLATERAL FLOW ASSAY FOR CRYPTOCOCCAL ANTIGEN: AN IMPORTANT ADVANCE TO IMPROVE THE CONTINUUM OF HIV CARE AND REDUCE CRYPTOCOCCAL MENINGITIS-RELATED MORTALITYTravel Medicine for the Extreme TravelerPassive prophylaxis with permethrin-treated tents reduces mosquito bites among North American summer campersMedical risks of wilderness hikingCryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness AnalysisSeroprevalence of histoplasmosis in Kampala, UgandaPhysician preferences for elements of effective consultations.Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study.Evolving Failures in the Delivery of Human Immunodeficiency Virus Care: Lessons From a Ugandan Meningitis Cohort 2006-2016.Unmasking cryptococcal meningitis immune reconstitution inflammatory syndrome in pregnancy induced by HIV antiretroviral therapy with postpartum paradoxical exacerbation.Hookworm infection is associated with decreased CD4+ T cell counts in HIV-infected adult Ugandans.Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohortsThe CSF Immune Response in HIV-1-Associated Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of Antiretroviral TherapyCryptococcal meningitis: A neglected NTD?Performance of cryptococcal antigen lateral flow assay using saliva in Ugandans with CD4 <100.Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis.Diagnostic performance of rapid diagnostic tests versus blood smears for malaria in US clinical practiceThe clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan childrenInfluence of hygiene on gastrointestinal illness among wilderness backpackers.Reduction of immune activation with chloroquine therapy during chronic HIV infectionCost-effective diagnostic checklists for meningitis in resource-limited settings.Gender differences among long-distance backpackers: A prospective study of women Appalachian Trail backpackersCentral nervous system cryptococcoma in a Ugandan patient with Human Immunodeficiency VirusStrongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis.Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda.Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitionsMethods of rapid diagnosis for the etiology of meningitis in adultsStandardized electrolyte supplementation and fluid management improves survival during amphotericin therapy for cryptococcal meningitis in resource-limited settings.Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure.
P50
Q21144604-F9868D60-770F-4BAE-A0CF-C5EA1FB0ADD5Q21144623-DA153C01-C144-462B-820D-ED3994A8DF77Q24273288-0E31AC26-B732-4315-A7B7-D20AFD803610Q24600270-A533910C-1B8D-4747-B2E9-5B3C9220DBACQ24610164-82EF17B2-D8DB-46C6-B141-D9A445D097CAQ24610933-2BC67881-DCC8-4095-8B2E-F52C2E289698Q24620256-3D248C6D-A56F-4E50-874D-512B3806C373Q24629367-7DD22918-6C6C-40F6-8320-D866371BD2B5Q24630287-10219B5B-49B7-42FA-B329-8E74559B6790Q24678422-E4AB305E-F748-47F5-A76E-E9DBA265F274Q26774211-6F8051B1-A545-47A7-A41E-79C06FA6357DQ26783210-A26153F3-84CD-4D0E-900C-9886080DD5C2Q27480972-BB305950-EDCB-415F-83E0-5FC62B3FAB12Q27485171-F0054A7D-591F-4494-AAEE-69F3D3EC3547Q28189299-1861E610-4967-4826-922D-8A628EE9BE38Q28274334-0A68EA4B-D4AD-4E1D-863B-08B48FA8594EQ30380987-68A92A61-5AD8-460A-A904-3D89B6105895Q33611434-22A82AE2-EF8F-45F9-AA24-55C723D89AD6Q33663591-F802942B-C1BF-4C46-A111-2AD25297969FQ33747751-40C98AC9-F548-46D7-A3FA-DFFE816C98E6Q33765829-266DB428-C79E-443F-95E0-C8D556CA3EC9Q33773331-3BAC3967-B1EC-4AE2-ACE4-C75BF43205E4Q33792332-F4CE3FE9-5621-4F75-A54E-D33B9511E612Q33793447-832F6C0C-0BE4-46DF-A6DE-C205443ABE9FQ33852819-B0B75D8A-EC26-4693-A113-AB8E4980B3BDQ33982206-4E507BEE-76C0-493F-8AE3-8DC81A520DE8Q34024416-70A1B729-5954-4D75-8E99-56EE19C6F026Q34028787-83049890-07FD-48A3-80F5-66DAB28A8117Q34039981-C50F830D-1EF3-4392-9BDD-7756D89BB3E9Q34295473-D44CEAC6-49FA-4BF3-BEF7-D0020459CED5Q34296062-162E9034-4FFD-43EB-95C2-99D5CB2AB9DCQ34331360-04B87F85-F876-406C-8A7D-5996409464F2Q34357317-1AEF1B92-2ACE-4E13-B385-01F750C6726EQ34436150-10F27CBF-94C8-4EE6-8F42-39FBF46A6C1EQ34469632-FAEC8975-960E-4F2C-96DF-110880628667Q34516367-38B39F7D-90CE-4CDC-990F-44958B01F14BQ34516548-51435FAB-ED72-4497-B42F-8EF224D258DFQ34554521-BD841C5E-012D-4088-B331-3A410DF8049AQ34801921-1B4FC906-1DCF-4AEA-921F-B18C474C5A48Q34932588-F3A73882-5CEF-4CB4-81EC-E688036056F8
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David R Boulware
@nl
David R Boulware
@sl
David R. Boulware
@en
David R. Boulware
@es
type
label
David R Boulware
@nl
David R Boulware
@sl
David R. Boulware
@en
David R. Boulware
@es
prefLabel
David R Boulware
@nl
David R Boulware
@sl
David R. Boulware
@en
David R. Boulware
@es
P106
P1153
7004238552
P2002
boulware_dr
P21
P31
P496
0000-0002-4715-0060